Business
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing
PURCHASE N.Y., March 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), was notified by the Nasdaq Stock Market LLC (“Nasdaq”) on September 12, 2024 that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive business days. As a result, Cognition was given 180 calendar days to regain compliance wi
About this update from Cognition Therapeutics, Inc.
[{"type":"image","alt":"Cognition Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cognition Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3G97CJjBroOGRUYevL.t.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22","width":250,"height":70}},"lazy":false},{"type":"text","content":"PURCHASE N.Y., March 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), was notified by the Nasdaq Stock Market LLC (“Nasdaq”) on September 12, 2024 that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive business days. As a result, Cognition was given 180 calendar days to regain compliance with the minimum bid price requirement, by achieving a closing bid price of at least $1.00 per share for 10 consecutive business days. The period to regain compliance with the minimum bid price requirement closed on March 11, 2025.","length":729,"tagName":"p"},{"type":"text","content":"On March 12, 2025, Cognition received notification from Nasdaq confirming the transfer of its listing to The Nasdaq Capital Market from The Nasdaq Global Market. This transfer is expected to take effect at market open on March 14, 2025. Cognition was granted an additional 180 calendar days to regain compliance with the minimum bid price requirement.","length":351,"tagName":"p"},{"type":"text","content":"The Company intends to monitor the closing bid price of our common stock and will consider available options to resolve the deficiency and regain compliance by September 8, 2025. If the closing bid price reaches at least $1.00 per share for a minimum of ten consecutive business days during this period, Nasdaq will provide written confirmation of compliance for continued listing on The Nasdaq Capital Market. If necessary, however, the company will seek stockholder approval to implement a reverse stock split. If the Company chooses to do so, the split must be completed no later than 10 business days prior to the expiration of ...